Table 1.
Clinical studies with immune checkpoint inhibitors (ICIs) in uveal melanoma.
| Authors | Treatment | Type of Study | No. of Enrolled Patients | Year |
|---|---|---|---|---|
| Zimmer et al. [19] | Ipilimumab | Phase II trial. Pre-treated and naïve patients. | 53 | 2015 |
| Maio et al. [17] | Ipilimumab | Retrospective analysis. Pre-treated patients. | 82 | 2013 |
| Kelderman et al. [20] | Ipilimumab | Retrospective analysis. Pre-treated patients. | 22 | 2013 |
| Luke et al. [15] | Ipilimumab | Retrospective, multi-center analysis. Pre-treated and naïve patients. | 39 | 2013 |
| Piulats Rodriguez et al. [21] | Ipilimumab | Phase II trial. Naïve patients | 32 | 2014 |
| Danielli et al. [10] | Ipilimumab | Retrospective analysis. Pre-treated patients. | 13 | 2012 |
| Khattak et al. [13] | Ipilimumab | Retrospective analysis, single center analysis. Pre-treated patients. | 5 | 2016 |
| Deo [22] | Ipilimumab | Retrospective, single center analysis. Pre-treated patients. | 24 | 2014 |
| Shaw et al. [23] | Ipilimumab | EAP. | 18 | 2012 |
| Joshua et al. [11] | Tremelimumab | Phase II trial. Naïve patients. | 11 | 2015 |
| Algazi et al. [9] | Pembrolizumab, Nivolumab, Atezolizumab | Retrospective, multi-center analysis. Pre-treated and naïve patients. | 56 | 2016 |
| Mignard et al [16] | Pembrolizumab, Nivolumab, Ipilimumab | Retrospective, multi-center analysis. | 100 | 2018 |
| Bender et al. [27] | Pembrolizumab, Nivolumab | Retrospective, multi-center analysis. Pre-treated patients. | 15 | 2017 |
| Heppt et al. [24] | Pembrolizumab, Nivolumab, Ipilimumab | Retrospective, multi-center analysis. Pre-treated and naïve patients. | 96 | 2017 |
| Piperno-Neumann et al. [25] | Pembrolizumab, Nivolumab | Retrospective, single center analysis. Naïve patients. | 21 | 2016 |
| Karydis et al. [12] | Pembrolizumab | Retrospective analysis. Pre-treated patients. | 25 | 2016 |
| Rossi et al. [18] | Pembrolizumab | Prospective. Naïve patients. | 17 | 2019 |
| Kottschade et al. [14] | Pembrolizumab | Retrospective, single-center analysis. Pre-treated patients. | 8 | 2016 |
| Van der Kooij et al. [26] | Pembrolizumab | Prospective. Pre-treated and naïve patients. | 17 | 2017 |
| Schadendorf et al. [27] | Nivolumab | Phase II. Pre-treated patients. | 75 | 2017 |
| Jung et al. [28] | Ipilimumab | Named patient use. Pre-treated patients. | 10 | 2017 |
| Shoushtari et al. [29] | Nivolumab, Ipilimumab | Expanded access program. | 6 | 2016 |
EAP: Expand Access Program.